This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
BD (BDX) Q1 Earnings Surpass Estimates, Margins Contract
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal first quarter.
Accuray (ARAY) Q2 Earnings Lag Estimates, Gross Margin Contracts
by Zacks Equity Research
Despite robust Services revenues, Accuray (ARAY) reports dismal second-quarter fiscal 2024 results.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is HCA Healthcare (HCA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how HCA Healthcare (HCA) and HealthEquity (HQY) have performed compared to their sector so far this year.
Company News for Jan 31, 2024
by Zacks Equity Research
Companies in The News Are: HCA,SYY,MSCI,NUE
Universal Health Services, Inc. (UHS) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
HCA Healthcare's (HCA) Q4 Earnings Beat on Improved Admissions
by Zacks Equity Research
HCA Healthcare (HCA) expects EPS in the range of $19.70-$21.20 for 2024, the midpoint being 7.6% higher than the 2023 figure.
HCA (HCA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for HCA (HCA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
HCA Healthcare (HCA) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of 16.83% and 4.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Moment of Truth Has Arrived for 2024 EPS Expectations
by Mayur Thaker
leading indicators for corporate profits continue to forecast a downturn, but stocks are priced for a soft landing - a dangerous combo.
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited fiscal first-quarter sales.
Earnings Growth & Price Strength Make HCA Healthcare (HCA) a Stock to Watch
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Is a Surprise Coming for HCA Healthcare (HCA) This Earnings Season?
by Zacks Equity Research
HCA Healthcare (HCA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Growth Stocks to Buy That Are Poised to Beat on Earnings
by Nalak Das
We have narrowed our search to five growth stocks that are poised to beat on earnings results next week. These are: PH, CMG, ETN, HCA, LII.
HCA Healthcare (HCA) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
The latest trading day saw HCA Healthcare (HCA) settling at $283.43, representing a -0.91% change from its previous close.
Why HCA Healthcare (HCA) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HCA (HCA) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for HCA (HCA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Can Higher Costs Affect HCA Healthcare's (HCA) Q4 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter results are likely to reflect increased admissions and a lower average length of stay.
Is HCA Healthcare (HCA) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Brokers Suggest Investing in HCA (HCA): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in HCA (HCA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
HCA Healthcare (HCA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
The latest trading day saw HCA Healthcare (HCA) settling at $287.77, representing a +1.04% change from its previous close.
Here's Why HCA Healthcare (HCA) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
HCA Healthcare, Inc. (HCA) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching HCA (HCA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
New to Investing? This 1 Medical Stock Could Be the Perfect Starting Point
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Here's Why HCA Healthcare (HCA) Fell More Than Broader Market
by Zacks Equity Research
HCA Healthcare (HCA) concluded the recent trading session at $279.33, signifying a -0.77% move from its prior day's close.